Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.80B
Revenue (ttm)	242.70M
Net Income (ttm)	-25.20M
Shares Out	16.65M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	61.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,661
Average Volume	17,630
Open	108.20
Previous Close	108.00
Day's Range	106.00 - 108.60
52-Week Range	83.30 - 159.60
Beta	0.75
RSI	39.15
Earnings Date	Feb 12, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 121
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.